Anika Therapeutics | ANIK - Cash And Equivalent


Anika Therapeutics reported $57.48M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Agenus USD 3.46M 6.08M Sep/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Anika Therapeutics USD 57.48M 509K Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Insmed USD 510.44M 175.68M Dec/2025
Integra LifeSciences USD 235.05M 2.86M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
J&J USD 19.71B 1.48B Dec/2025
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Merit Medical Systems USD 446.4M 53.95M Dec/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Stryker USD 4.01B 755M Dec/2025
Surmodics USD 36.11M 11.81M Sep/2024
Veracyte USD 362.58M 47M Dec/2025
Xencor USD 54.07M 25.78M Dec/2025
Zimmer Biomet Holdings USD 591.9M 700.8M Dec/2025